GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » Beneish M-Score

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Beneish M-Score : 0.00 (As of May. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for ZELTIQ Aesthetics's Beneish M-Score or its related term are showing as below:

During the past 8 years, the highest Beneish M-Score of ZELTIQ Aesthetics was 0.00. The lowest was 0.00. And the median was 0.00.


ZELTIQ Aesthetics Beneish M-Score Historical Data

The historical data trend for ZELTIQ Aesthetics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics Beneish M-Score Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Beneish M-Score
Get a 7-Day Free Trial -1.84 -3.10 -1.72 -0.48 -2.52

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -0.46 -0.94 -1.29 -2.52

Competitive Comparison of ZELTIQ Aesthetics's Beneish M-Score

For the Medical Devices subindustry, ZELTIQ Aesthetics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZELTIQ Aesthetics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ZELTIQ Aesthetics's Beneish M-Score falls into.



ZELTIQ Aesthetics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ZELTIQ Aesthetics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1947+0.528 * 1.0015+0.404 * 0.6157+0.892 * 1.3868+0.115 * 1.1215
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9896+4.679 * -0.080608-0.327 * 1.1338
=-2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec16) TTM:Last Year (Dec15) TTM:
Total Receivables was $55.3 Mil.
Revenue was 105.11 + 95.157 + 89.465 + 64.469 = $354.2 Mil.
Gross Profit was 75.744 + 66.75 + 61.944 + 46.24 = $250.7 Mil.
Total Current Assets was $165.3 Mil.
Total Assets was $214.3 Mil.
Property, Plant and Equipment(Net PPE) was $12.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.6 Mil.
Selling, General, & Admin. Expense(SGA) was $211.9 Mil.
Total Current Liabilities was $72.8 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Net Income was 10.277 + 5.189 + -4.902 + -9.87 = $0.7 Mil.
Non Operating Income was -0.954 + 0.498 + 1.409 + 0.646 = $1.6 Mil.
Cash Flow from Operations was -5.058 + 15.768 + 14.747 + -9.084 = $16.4 Mil.
Total Receivables was $33.4 Mil.
Revenue was 78.225 + 61.202 + 64.431 + 51.558 = $255.4 Mil.
Gross Profit was 52.385 + 45.161 + 46.315 + 37.18 = $181.0 Mil.
Total Current Assets was $121.8 Mil.
Total Assets was $178.8 Mil.
Property, Plant and Equipment(Net PPE) was $7.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.4 Mil.
Selling, General, & Admin. Expense(SGA) was $154.4 Mil.
Total Current Liabilities was $53.4 Mil.
Long-Term Debt & Capital Lease Obligation was $0.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(55.269 / 354.201) / (33.359 / 255.416)
=0.156039 / 0.130607
=1.1947

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(181.041 / 255.416) / (250.678 / 354.201)
=0.708808 / 0.707728
=1.0015

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (165.264 + 12.14) / 214.345) / (1 - (121.802 + 6.969) / 178.827)
=0.172344 / 0.279913
=0.6157

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=354.201 / 255.416
=1.3868

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.423 / (2.423 + 6.969)) / (3.627 / (3.627 + 12.14))
=0.257986 / 0.230037
=1.1215

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(211.934 / 354.201) / (154.438 / 255.416)
=0.598344 / 0.604653
=0.9896

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 72.759) / 214.345) / ((0.138 + 53.4) / 178.827)
=0.339448 / 0.299384
=1.1338

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.694 - 1.599 - 16.373) / 214.345
=-0.080608

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ZELTIQ Aesthetics has a M-score of -2.52 suggests that the company is unlikely to be a manipulator.


ZELTIQ Aesthetics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines